trending Market Intelligence /marketintelligence/en/news-insights/trending/StCVeC4AMHAE_4DtC5X0Tg2 content esgSubNav
In This List

Approval for Astrazeneca, Merck & Co.; designation for Savara

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Approval for Astrazeneca, Merck & Co.; designation for Savara

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 3.

Approvals

* AstraZeneca PLC and Merck & Co. Inc.'s Lynparza as a stand-alone maintenance therapy for BRCA-mutated pancreatic cancer that has spread but has not progressed for at least 16 weeks following first-line platinum-based chemotherapy.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Breakthrough therapy

* Savara Inc.'s Molgradex for autoimmune pulmonary alveolar proteinosis.